At Enzymaticas Annual General Meeting today 6 May 2013, Christian Westin Jansson was elected new Chairman of the Board of Directors and Anders Jungbeck was elected new Board member. The meeting further resolved, inter alia, to implement an incentive program to employees and external Board members who work actively for the Company, and to authorize the Board to issue new shares.
The AGM voted in favour of adopting the income statements and balance sheets for the group and the parent company, and resolved that the funds available at the general meeting should be carried forward and that thus no dividend should be paid for the financial year 2012.
The AGM discharged the Board members and the CEO from liability, reelected the ordinary Board members Fredrik Lindberg and Jörgen Rexö and elected Christian Westin Jansson as new Chairman of the Board and Anders Jungbeck as new Board member. No fees will be paid to the Board
Furthermore, the AGM authorized the Board to resolve on the issue of no more than 2,000,000 new shares, with or without a deviation from the shareholders’ preferential right, for the purpose of enabling the raise of capital to finance the Company’s continuous expansion and for the purpose
enabling company acquisitions or acquisition of all or parts of business entities.
Last the AGM resolved, in accordance with the Board’s proposal, to implement a long term incentive program in the form of an option program comprising employees and external active Board members of Enzymatica. The new Option Program 2013/2017 shall include a maximum of 850,000 options.
For more information, please contact:
Michael Edelborg Christensen, CEO
Telephone: +46 (0)76-814 41 66